Astellas Clotting Drug Increased Bleeding In French Phase II Trial
This article was originally published in PharmAsia News
An Astellas blood-clotting drug was shown in a Phase II trial to increase bleeding as much as four times normal in some heart patients
You may also be interested in...
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.